CBD shows promise for opioid cravings and pain in early trial

NCT ID NCT05076370

Completed Symptom relief Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested whether cannabidiol (CBD) could safely help people with both opioid use disorder and chronic pain. Seven adults on methadone or buprenorphine received single doses of CBD (400, 800, or 1200 mg) or a placebo in a crossover design. Researchers measured safety, sedation, cognitive function, and effects on pain and cravings. The trial is complete, but results are not yet widely reported.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cannabidiol (CBD)
What this could lead to: If it works, this could point toward a safe, non-addictive option to help manage pain and reduce cravings in people with opioid use disorder.
What could go wrong: This was a very early, tiny study with only 7 people. It only tested single doses, not long-term use. Results may not apply to everyone, and side effects or lack of benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADDICTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Behavior, Addictive chronic pain syndrome opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADDICTION

Contacts and locations

Locations

Veteran Affairs Hospital

West Haven, Connecticut, 06516, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.